H
36.15
0.13 (0.36%)
| Penutupan Terdahulu | 36.02 |
| Buka | 35.62 |
| Jumlah Dagangan | 207,441 |
| Purata Dagangan (3B) | 496,730 |
| Modal Pasaran | 1,287,471,488 |
| Harga / Jualan (P/S) | 7.71 |
| Harga / Buku (P/B) | 22.53 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 17 Mar 2025 - 21 Mar 2025 |
| Margin Keuntungan | -19.75% |
| Margin Operasi (TTM) | 2.68% |
| EPS Cair (TTM) | -0.950 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 43.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 322.90% |
| Nisbah Semasa (MRQ) | 1.55 |
| Aliran Tunai Operasi (OCF TTM) | 4.27 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -100.52 M |
| Pulangan Atas Aset (ROA TTM) | -1.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -50.23% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Harrow, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.1
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 1.13 |
|
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 13.49% |
| % Dimiliki oleh Institusi | 59.26% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Opaleye Management Inc. | 30 Sep 2024 | 3,990,000 |
| First Turn Management, Llc | 30 Sep 2024 | 326,582 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |